COVID-19 Vaccine-Related Vogt–Koyanagi–Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review

Han, Ruyi; Xu, Gezhi; Ding, Xinyi

doi:10.3390/vaccines10111792

Cited by 6 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As related to vaccination against the coronavirus disease 2019 (COVID- 19), this was implemented to eliminate the SARS-CoV-2 pandemic, providing significant protection against infection and the development of multi-organ acute respiratory distress syndrome. However, subsequent studies have demonstrated potential adverse events in vaccinated patients, including ocular complications: non-arteritic anterior ischemic optic neuropathy (NAION), central serous chorioretinopathy (CSC), and Vogt-Koyanagi-Harada (VKH) disease have been reported [2][3][4][5]7].…”

Section: Introductionmentioning

confidence: 99%

The Implications of SARS-CoV-2 Infection in a Series of Neuro-Ophthalmological Manifestations—Case Series and Literature Review

Anton

Bogdănici

Brănişteanu

et al. 2023

JCM

View full text Add to dashboard Cite

The global pandemic impact of the COVID-19 infection included clinical manifestations that affected several organs and systems, with various neuro-ophthalmological manifestations associated with the infection. These are rare and occur either secondary to the presence of the virus or by an autoimmune mechanism secondary to viral antigens. The manifestations are atypical, being present even in the absence of the systemic symptoms typical of a SARS-CoV-2 infection. In this article, we introduce a series of three clinical cases with neuro-ophthalmological manifestations associated with COVID infection that were shown in Ophthalmology Clinic of St. Spiridon Emergency Hospital. Case 1 is that of a 45-year-old male patient with no personal history of general pathology or ophthalmology, with binocular diplopia, painful red eyes, and lacrimal hypersecretion with a sudden onset of about 4 days. Based on the evaluations, a positive diagnosis of orbital cellulitis in both eyes is made. Case 2 is that of a 52-year-old female patient with general PPA (personal pathological antecedents) of SARS-CoV-2 infection 1 month prior to presentation with decreased visual acuity in the right eye and a positive central scotoma, preceded by photopsia and vertigo with balance disorders. The diagnosis is made at the right eye for retrobulbar optic neuritis and post-SARS-CoV-2 infection status. The last clinical case is that of a 55-year-old male patient known to have high blood pressure (HBP) with a sudden, painless decrease in VARE approximately 3 weeks post-SARS-CoV-2 immunization (Pfizer vaccine first dose). The diagnosis is made after consulting all the RE results for central retinal vein thrombosis. Conclusions: Although the cases were quickly and efficiently investigated and the treatment was administered adequately by a multidisciplinary team (cases 1 and 3), the evolution was not favorable in all three situations. Atypical neuro-ophthalmological manifestations can also be present in the absence of systemic symptoms typical of SARS-CoV-2 infection.

show abstract

Section: Introductionmentioning

confidence: 99%

The Implications of SARS-CoV-2 Infection in a Series of Neuro-Ophthalmological Manifestations—Case Series and Literature Review

Anton

Bogdănici

Brănişteanu

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

Bbibp-corv/prednisolone-acetate/prednisone

2022

Reactions Weekly

View full text Add to dashboard Cite

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease

Gao

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Vogt-Koyanagi-Harada (VKH) disease is a rare and serious ocular adverse reaction following COVID-19 vaccination. This study aimed to evaluate the clinical features, diagnosis and management of COVID-19 vaccine-associated VKH disease. Case reports of VKH disease after COVID-19 vaccination were collected up to February 11, 2023 for retrospective analysis. Twenty-one patients (9 males and 12 females) were included, with a median age of 45 years (range 19–78), from three main regions, Asia (12/21), the Mediterranean region (4/21), and South America (5/21). Fourteen patients developed symptoms after the first dose of the vaccine, and 8 after the second dose. Vaccines included mRNA vaccine (10 cases), virus vector vaccine (6 cases), and inactivated vaccine (5 cases). The average time interval from vaccination to onset of symptoms was 7.5 days (range 12 hours to 4 weeks). All 21 patients experienced visual impairment after vaccination, with 20 cases involving both eyes. Sixteen patients showed symptoms of meningitis. Serous retinal detachment was observed in 16 patients, choroidal thickening was observed in 14, aqueous cell in 9, and subretinal fluid in 6. CSF pleocytosis was detected in 7 patients and skin symptoms were found in 3 patients. All patients received corticosteroid therapy, and 8 also received immunosuppressive agents. All patients recovered well, with a mean recovery time of 2 months. Early diagnosis and early treatment are crucial to the prognosis of patients with VKH after vaccination with COVID-19 vaccine. The risk of vaccination against COVID-19 in patients with a history of VKH disease should be evaluated clinically.

show abstract

COVID-19 Vaccine-Related Vogt–Koyanagi–Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review

Cited by 6 publications

References 37 publications

The Implications of SARS-CoV-2 Infection in a Series of Neuro-Ophthalmological Manifestations—Case Series and Literature Review

The Implications of SARS-CoV-2 Infection in a Series of Neuro-Ophthalmological Manifestations—Case Series and Literature Review

Bbibp-corv/prednisolone-acetate/prednisone

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease

Contact Info

Product

Resources

About